— A New Trial Marks Expanded Phase 3 Development of MDV3100 into Earlier-Stage Disease — Medivation, Inc. and Astellas Pharma Inc. today announced the launch of a second Phase 3 clinical trial of their investigational drug MDV3100. This trial marks the expansion of the Phase 3 development of their novel, triple-acting oral androgen receptor antagonist [...]
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced the publication of results from their randomized Phase 2 trial of custirsen for men with advanced prostate cancer in the September 20, 2010 Journal of Clinical Oncology. According to their announcement, the trial results showed a survival benefit with their investigational agent OGX-011/TV1011 (custirsen) in men with advanced prostate [...]
Researchers at the Cedars-Sinai Medical Center in Los Angeles set out to see if there are any health benefits to be derived from a massage, or is a massage just relaxing to your muscles? […]
Leukine, a granulocyte macrophage colony-stimulating factor (GM-CSF), is a hormone therapy that does not have an effect on a man’s testosterone production. Leukine is used by many physicians who are knowledgeable about the value of second line hormone therapy. Leukine works by stimulating the white blood cells (both increasing the overall production of the white [...]
One of the earliest hormone therapies (ADT) given to men to treat prostate cancer was estrogen. Estrogen, commonly known as the female hormone, was used as an ADT treatment in the early 1950s. […]